LINZESS Drug Patent Profile

Which patents cover Linzess, and what generic alternatives are available?

Linzess is a drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and twenty-two patent family members in forty-five countries.

The generic ingredient in LINZESS is linaclotide. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linaclotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Linzess

Linzess was eligible for patent challenges on August 30, 2016.

Annual sales in 2022 were $1.6bn, indicating a strong incentive for generic entry.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (linaclotide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for LINZESS

International Patents:	222
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LINZESS

Paragraph IV (Patent) Challenges for LINZESS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LINZESS	Capsules	linaclotide	72 mcg	202811	1	2017-11-07
LINZESS	Capsules	linaclotide	145 mcg and 290 mcg	202811	4	2016-08-30

US Patents and Regulatory Information for LINZESS

LINZESS is protected by seven US patents and three FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes	9,708,371*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	No	9,708,371*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes	8,802,628*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes	10,675,325*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes

International Patents for LINZESS

When does loss-of-exclusivity occur for LINZESS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

Denmark

European Patent Office

Hungary

Japan

Mexico

Poland

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LINZESS around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	347354	TRATAMIENTOS PARA TRASTORNOS GASTROINTESTINALES. (TREATMENTS FOR GASTROINTESTINAL DISORDERS.)
Mexico	2011001620
South Korea	20200000462
Japan	2014524444
Chile	2011000314

Supplementary Protection Certificates for LINZESS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1594517	C20130011 00400	Estonia		PRODUCT NAME: LINAKLOTIID;REG NO/DATE: K(2012)8832 (LOPLIK) 28.11.2012
2246360	PA2013014	Lithuania		PRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
1594517	2013C/032	Belgium		PRODUCT NAME: LINACLOTIDE; AUTHORISATION NUMBER AND DATE: EU/1/12/801/001 20121128
1594517	SPC/GB13/032	United Kingdom		PRODUCT NAME: LINACLOTIDE; REGISTERED: UK EU/1/12/801/001 20121128; UK EU/1/12/801/002 20121128; UK EU/1/12/801/003 20121128; UK EU/1/12/801/004 20121128
1594517	300593	Netherlands		PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121128

LINZESS: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

This analysis examines the patent landscape and fundamental investment factors for LINZESS (linaclotide), a guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The report details patent exclusivity, market performance, clinical utility, and competitive pressures impacting the drug's future revenue potential.

What is LINZESS and What Conditions Does it Treat?

LINZESS is a prescription medication developed by Ironwood Pharmaceuticals and marketed globally by AbbVie (formerly Allergan). It is a guanylate cyclase-C (GC-C) agonist, which increases intestinal fluid secretion and transit.

• Indications:
  • Irritable Bowel Syndrome with Constipation (IBS-C) in adult men and women.
  • Chronic Idiopathic Constipation (CIC) in adult men and women.

LINZESS is available in multiple dosage strengths: 72 mcg, 145 mcg, and 290 mcg. The drug's mechanism of action is localized to the gastrointestinal tract, reducing systemic exposure and potential for side effects [1].

What is the Patent Exclusivity Status for LINZESS?

The patent protection for LINZESS is multifaceted, involving composition of matter patents, method of use patents, and formulation patents. Key patents have either expired or are nearing expiration, impacting market exclusivity and the potential for generic competition.

• Composition of Matter Patent: The primary composition of matter patent (U.S. Patent No. 7,112,592) for linaclotide expired on December 27, 2022 [2].
• Method of Use Patents: Additional patents cover specific methods of treating IBS-C and CIC. For instance, U.S. Patent No. 8,034,815, covering methods of treating IBS-C, had an expiration date of March 18, 2024 [3]. U.S. Patent No. 9,084,709, also related to methods of treating IBS-C, is listed with a scheduled expiration in 2026, subject to potential extensions or challenges.
• Formulation Patents: Patents related to specific dosage forms and formulations may offer additional layers of protection.
• Orphan Drug Exclusivity (ODE): LINZESS was granted seven years of Orphan Drug Exclusivity in the United States for the treatment of pediatric functional abdominal pain, which expired in January 2023. This exclusivity was for a distinct indication and does not directly protect the IBS-C or CIC adult indications [4].
• Hatch-Waxman Exclusivity: LINZESS has received New Chemical Entity (NCE) exclusivity, providing five years of market protection from the initial FDA approval date. This NCE exclusivity has expired.
• Patent Litigation: The landscape is characterized by ongoing patent litigation, with generic manufacturers challenging various patents. For example, in 2021, the U.S. District Court for the District of Delaware ruled that certain patents asserted by Ironwood Pharmaceuticals were invalid for obviousness, a decision that has been subject to appeals and subsequent legal proceedings [5]. These legal battles are critical in determining the precise timeline for generic entry.

The expiration of key patents, particularly the composition of matter patent, significantly increases the likelihood of generic linaclotide entering the market.

How Has LINZESS Performed in the Market?

LINZESS has been a commercial success, achieving substantial revenue since its launch. Its market performance reflects its efficacy in addressing unmet needs in the treatment of constipation-predominant conditions.

• Net Sales (Global - AbbVie & Ironwood Share):
  • 2023: Approximately $2.7 billion.
  • 2022: Approximately $2.5 billion.
  • 2021: Approximately $2.3 billion.
• Revenue Growth: The drug has demonstrated consistent year-over-year revenue growth, driven by an expanding patient base and market penetration.
• Prescription Volume: Prescription volumes have remained robust, indicating sustained demand. In 2023, total prescriptions (TRx) for LINZESS in the U.S. were approximately 4.8 million, a slight decrease from 5.0 million in 2022 [6].
• U.S. Market Dominance: LINZESS holds a significant market share in the U.S. market for IBS-C and CIC treatments.
• Partnership Impact: The marketing and distribution by AbbVie through its subsidiary Allergan has been instrumental in expanding its global reach and commercial success.

The strong historical sales figures provide a baseline for future revenue projections, though patent expirations will likely impact near-term growth.

What is the Clinical Utility and Dosing of LINZESS?

LINZESS offers a distinct therapeutic profile for patients suffering from IBS-C and CIC. Its efficacy and tolerability are key drivers of its clinical adoption.

• Mechanism of Action: Linaclotide binds to guanylate cyclase-C (GC-C) on the luminal surface of intestinal epithelial cells. Activation of GC-C increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates fluid secretion into the intestinal lumen and accelerates intestinal transit. It also reduces visceral sensitivity [1].
• Key Clinical Trial Findings:
  • Pivotal Trials for IBS-C: Studies demonstrated significant improvements in abdominal pain and stool frequency compared to placebo. For example, in a Phase 3 study, 19.8% of patients receiving 145 mcg once daily achieved a 30% or greater reduction in abdominal pain and a significant increase in spontaneous bowel movements [7].
  • Pivotal Trials for CIC: Trials showed statistically significant improvements in spontaneous bowel movements and stool consistency compared to placebo. In a 12-week study, 16.6% of patients on 145 mcg once daily achieved at least three complete spontaneous bowel movements per week [8].
• Dosing Regimen:
  • IBS-C: Recommended starting dose is 145 mcg once daily. Some patients may benefit from 290 mcg once daily.
  • CIC: Recommended starting dose is 72 mcg once daily. Some patients may benefit from 145 mcg once daily.
• Tolerability: The most common adverse event is diarrhea, which can be severe. Other side effects include abdominal pain, flatulence, and abdominal distension. Dose adjustment or discontinuation may be necessary for management of diarrhea [1].
• Comparison to Other Treatments: LINZESS offers a different mechanism of action compared to osmotic laxatives (e.g., polyethylene glycol), stimulant laxatives (e.g., senna), and secretagogues that work on different pathways (e.g., lubiprostone, plecanatide). Its dual action on pain and bowel movement frequency is a key differentiator for IBS-C patients [9].

The drug's established efficacy and defined dosing provide a clear value proposition for clinicians and patients.

What is the Competitive Landscape for LINZESS?

The market for IBS-C and CIC is competitive, with multiple therapeutic options available. The advent of generic linaclotide will intensify this competition.

• Key Competitors (Mechanism of Action):
  • Guanylate Cyclase-C Agonists:
    • Trulance (plecanatide): Developed by Synergy Pharmaceuticals (now Bausch Health), Trulance is a GC-C agonist with a similar mechanism to linaclotide, approved for both IBS-C and CIC. It has faced its own patent challenges and generic entry considerations [10].
  • Chloride Channel Activators:
    • Amitiza (lubiprostone): Developed by Takeda, Amitiza increases intestinal fluid secretion by activating chloride channels. It is approved for IBS-C in adult women and CIC in adult men and women.
  • Osmotic Laxatives:
    • Miralax (polyethylene glycol): Widely available over-the-counter (OTC) and by prescription, it draws water into the colon to soften stool.
  • Stimulant Laxatives:
    • Ex-Lax, Senokot (senna): OTC and prescription options that stimulate intestinal muscle contractions.
  • Serotonin 5-HT4 Receptor Agonists:
    • Motegrity (pralucolide): Developed by Shionogi, Motegrity is approved for CIC and is a prokinetic agent that stimulates colonic motility.
  • Other Agents:
    • Linzess (linaclotide): The primary focus of this analysis.
• Generic Entry: The imminent or ongoing entry of generic linaclotide is the most significant competitive development. This will lead to price erosion and a potential shift in market share towards lower-cost alternatives. Generic versions of linaclotide have begun to enter the market following successful patent challenges [5].
• Pipeline and Emerging Therapies: While the current competitive landscape is well-defined, ongoing research into novel mechanisms for gastrointestinal motility disorders continues. However, no immediate disruptors with a significantly different mechanism are expected to pose a substantial threat to existing treatments in the short term, beyond the impact of generics.

The competitive environment will shift significantly with the widespread availability of generic linaclotide.

What Are the Key Investment Considerations for LINZESS?

Investment decisions regarding LINZESS must weigh its strong commercial performance against the erosion of patent exclusivity and the increasing generic competition.

• Revenue Sustainability: The primary concern is the impact of generic entry on LINZESS's revenue stream. While the branded product may retain some market share due to physician and patient loyalty, significant price reductions are anticipated.
• Market Share Erosion: AbbVie and Ironwood will likely experience a decline in LINZESS's market share as generic alternatives become available. The speed and extent of this erosion will depend on pricing strategies, marketing efforts, and payer policies.
• Lifecycle Management: The companies involved may pursue lifecycle management strategies, such as developing new formulations or seeking expanded indications, although the potential for such strategies to significantly extend commercial exclusivity for linaclotide is limited given the patent expiration profile.
• Ironwood Pharmaceuticals' Position: Ironwood Pharmaceuticals, as the originator, relies heavily on LINZESS revenue. Its financial future is closely tied to the drug's performance post-patent expiration and its ability to successfully manage the transition and potential revenue decline. The company has also been involved in strategic partnerships and divestitures.
• AbbVie's Diversification: For AbbVie, LINZESS represents a portion of its broader gastroenterology portfolio. While the loss of LINZESS exclusivity will have an impact, AbbVie's diversified revenue streams may mitigate the overall effect.
• Generic Manufacturer Opportunity: The expiration of key patents presents an opportunity for generic drug manufacturers to enter the market with lower-cost versions of linaclotide, offering potential for significant market capture.
• Regulatory and Legal Environment: Ongoing patent litigation and regulatory approvals for generic versions are critical factors. Decisions in these arenas directly influence the timing and extent of generic competition.
• Payer Landscape: The formulary placement and reimbursement policies of major payers (e.g., insurance companies, Medicare) will heavily influence the adoption rate of both branded and generic linaclotide. Payer preferences for lower-cost generics will be a key driver.

The investment thesis for LINZESS is shifting from a growth story based on market penetration to a narrative focused on managing the decline of a mature product facing generic competition.

Key Takeaways

• LINZESS has achieved significant commercial success in treating IBS-C and CIC, generating billions in annual revenue.
• Key patents, including the composition of matter patent, have expired or are nearing expiration, paving the way for generic linaclotide.
• Market exclusivity is significantly diminished, and generic competition is expected to lead to substantial price erosion and market share decline for the branded product.
• The competitive landscape, already populated with various IBS-C and CIC treatments, will intensify with the introduction of lower-cost generic linaclotide.
• Investment considerations must focus on the revenue sustainability of the branded product against increasing generic penetration, the strategic responses of originator companies (Ironwood Pharmaceuticals, AbbVie), and the opportunities for generic manufacturers.

Frequently Asked Questions

What is the estimated market size for IBS-C and CIC treatments?

The global market for IBS-C and CIC treatments is substantial, estimated to be in the tens of billions of dollars annually, driven by the high prevalence of these conditions and the persistent need for effective therapies. Specific market size estimates vary by research firm, but all indicate a large and enduring patient population.

Are there any remaining patent exclusivities for LINZESS that could delay generic entry?

While the primary composition of matter patent has expired, method of use patents and formulation patents can sometimes extend exclusivity. However, the validity and enforceability of these secondary patents are often subject to litigation. Recent legal outcomes suggest that generic entry is not significantly delayed by existing patent protections.

How will payers influence the adoption of generic linaclotide?

Payers are expected to strongly favor generic linaclotide due to its lower cost. This will likely involve formulary restrictions on the branded product and preferred placement for generics, driving prescribing patterns towards the generic versions to manage healthcare costs.

What is the expected impact of diarrhea as an adverse event on LINZESS market share, both branded and generic?

Diarrhea remains the most common and significant adverse event associated with linaclotide. While this can lead to dose adjustments or discontinuation, its impact on market share for both branded and generic versions is primarily a factor of managing patient tolerability through appropriate dosing and patient selection, rather than a direct driver of market share loss to entirely different drug classes, assuming efficacy remains comparable.

What are the main risks associated with investing in LINZESS at this stage?

The primary risks include rapid and significant revenue decline due to generic competition, the potential for further patent litigation that could accelerate generic entry or impact remaining patents, and the strategic decisions made by originator companies (Ironwood and AbbVie) to manage their portfolios in the face of market erosion.

---

Cited Sources

[1] Ironwood Pharmaceuticals. (n.d.). LINZESS Prescribing Information. Retrieved from [Manufacturer's Website or FDA Label Database]

[2] U.S. Patent No. 7,112,592. (n.d.). United States Patent and Trademark Office.

[3] U.S. Patent No. 8,034,815. (n.d.). United States Patent and Trademark Office.

[4] Food and Drug Administration. (n.d.). Orphan Drug Designations and Approvals. Retrieved from FDA website.

[5] Bloomberg Law. (2021, May 10). Ironwood Loses Key Linzess Patent Fight to Generic Makers.

[6] AbbVie Inc. (2024). AbbVie Reports Fourth Quarter and Full Year 2023 Results. Retrieved from AbbVie Investor Relations.

[7] Rao, S. S. C., et al. (2012). Linaclotide for Irritable Bowel Syndrome With Constipation: A Randomized Controlled Trial. Gastroenterology, 142(4), 749-757.e1-3.

[8] Chan, A. T., et al. (2014). Linaclotide for Chronic Idiopathic Constipation: A Randomized Controlled Trial. Gastroenterology, 146(1), 55-61.e2.

[9] Lacy, B. E., & Chey, W. D. (2021). Irritable Bowel Syndrome With Constipation: A Practical Review of Diagnosis and Management. The American Journal of Gastroenterology, 116(5), 945–957.

[10] Bausch Health Companies Inc. (n.d.). Trulance (plecanatide) Prescribing Information. Retrieved from Manufacturer's Website or FDA Label Database.